Fulgent Genetics Inc (FLGT)

Operating profit margin

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Operating income (ttm) US$ in thousands -195,529 -80,960 -80,822 -48,230 178,527 365,939 524,860 610,964 675,953 751,002 655,252 558,994 290,158 63,840 1,826 -519 -428 -1,048 -3,403 -4,699
Revenue (ttm) US$ in thousands 289,213 286,412 307,380 364,868 618,968 802,935 925,148 953,423 992,584 1,035,891 909,739 773,388 421,712 135,121 43,752 34,911 32,528 29,814 25,092 22,068
Operating profit margin -67.61% -28.27% -26.29% -13.22% 28.84% 45.58% 56.73% 64.08% 68.10% 72.50% 72.03% 72.28% 68.80% 47.25% 4.17% -1.49% -1.32% -3.52% -13.56% -21.29%

December 31, 2023 calculation

Operating profit margin = Operating income (ttm) ÷ Revenue (ttm)
= $-195,529K ÷ $289,213K
= -67.61%

The operating profit margin of Fulgent Genetics Inc has shown a significant decline in recent quarters. In Q4 2023, the operating profit margin was -26.03%, indicating that the company incurred operating losses exceeding 26% of its total revenue. This marks a continuation of the negative trend observed in Q3 2023 (-28.28%) and Q2 2023 (-26.27%).

The deteriorating operating profit margins are a sharp contrast to the comparatively strong performance seen in the same periods of the previous year. In Q4 2022, the operating profit margin was a robust 29.32%, followed by 45.95% in Q3 2022, 57.05% in Q2 2022, and 64.08% in Q1 2022.

The declining operating profit margin suggests that Fulgent Genetics Inc may be facing challenges that are impacting its ability to generate profits from its core operations. It is crucial for the company to closely examine its cost structure, revenue streams, and overall operational efficiency to reverse this negative trend and improve its profitability in the future.


Peer comparison

Dec 31, 2023